The nurse's role in the prevention of cervical cancer among underserved and minority populations

Journal of Community Health

Volumn 34, Issue 2, 2009, Pages 135-143

  Rogers, Norma Martinez ^a   Cantu, Adelita G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cervical cancer; Human papillomavirus; Nurses; Screening; Vaccination

Indexed keywords

ADENOCARCINOMA; ADULT; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; COST OF ILLNESS; FEMALE; HUMANS; MEDICALLY UNDERSERVED AREA; MINORITY GROUPS; NURSE'S ROLE; PAPILLOMAVIRIDAE; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 62149134196     PISSN: 00945145     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10900-008-9134-4     Document Type: Article

References (74)

1. Ries, L., Harkins, D., Krapcho, M., Mariotto, A., Miller, B. A., Feuer, E. J., et al. (Eds.), SEER Cancer Statistics Review, 1975-2004. Bethesda: National Cancer Institute, based on November 2005 SEER data submission, posted to the SEER web site. Available at http://seer.cancer.gov/csr/1975-2004/. Accessed 3 February 2008.
2. ACS. American Cancer Society: Cancer Facts & Figures. (2008). Available at http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed 1 April 2008.
3. JM Walboomers MV Jacobs MM Manos 1999 Human papillomavirus is a necessary cause of invasive cervical cancer worldwide Journal of Pathology 189 1 12 19
4. FX Bosch A Lorincz N Munoz CJ Meijer KV Shah 2002 The causal relation between human papillomavirus and cervical cancer Journal of Clinical Pathology 55 4 244 265
5. EF Dunne ER Unger M Sternberg 2007 Prevalence of HPV infection among females in the United States Jama 297 8 813 819
6. CDC. (2007). The pink book: Epidemiology and prevention of vaccine preventable diseases. Updated 10th ed.
7. RP Viscidi M Schiffman A Hildesheim 2004 Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica Cancer Epidemiology, Biomarkers and Prevention 13 2 324 327
8. U.S. Census Bureau. (2004). U.S. interim projections by age, sex, race, and hispanic origin. Available at http://www.census.gov/ipc/www/usinterimproj/. Accessed 5 March 2008.
9. D Saslow PE Castle JT Cox 2007 American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors CA: A Cancer Journal for Clinicians 57 1 7 28
10. VB Benard HW Lawson CR Eheman C Anderson W Helsel 2005 Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women Obstetrics and Gynecology 105 6 1323 1328
11. JS Smith L Lindsay B Hoots 2007 Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update International Journal of Cancer 121 621 632
12. EM de Villiers C Fauquet TR Broker HU Bernard H zur Hausen 2004 Classification of papillomaviruses Virology 324 17 27
13. X Castellsague M Diaz S de Sanjose 2006 Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention Journal of the National Cancer Institute 98 5 303 315
14. AP Vizcaino V Moreno FX Bosch 2000 International trends in incidence of cervical cancer: II. Squamous-cell carcinoma International Journal of Cancer 86 3 429 435
15. AP Vizcaino V Moreno FX Bosch N Munoz XM Barros-Dios DM Parkin 1998 International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas International Journal of Cancer 75 4 536 545
16. S Bulk O Visser L Rozendaal RH Verheijen CJ Meijer 2005 Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women International Journal of Cancer 113 6 1005 1009
17. JF Krane SR Granter CE Trask CL Hogan KR Lee 2001 Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: A study of 49 cases Cancer 93 1 8 15
18. H Mitchell G Medley I Gordon G Giles 1995 Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: No strong evidence of benefit British Journal of Cancer 71 4 894 897
19. SS Raab 2000 Can glandular lesions be diagnosed in pap smear cytology? Diagnostic Cytopathology 23 2 127 133
20. M Einstein R Burk 2001 Persistent human papillomavirus infection: Definitions and clinical implications Papillomavirus Report 12 119
21. SK Kjaer AJ van den Brule G Paull 2002 Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study Bmj 325 7364 572
22. JL Benedet H Bender H Jones 3rd HY Ngan S Pecorelli 2000 FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology International Journal of Gynaecology and Obstetrics 70 2 209 262
23. Wright, T. C., Jr. (2006). HPV DNA testing for cervical cancer screening. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynaecology and Obstetrics, 95(Suppl 1), S239-S246.
24. TC Wright P Van Damme HJ Schmitt A Meheus 2006 Chapter 14: HPV vaccine introduction in industrialized countries Vaccine 24 Suppl 3 S122 S131
25. M Stanley 2006 Immune responses to human papillomavirus Vaccine 24 Suppl 1 S16 S22
26. A Le Bon DF Tough 2002 Links between innate and adaptive immunity via type I interferon Current Opinion in Immunology 14 4 432 436
27. AN Theofilopoulos R Baccala B Beutler DH Kono 2005 Type I interferons (alpha/beta) in immunity and autoimmunity Annual Review of Immunology 23 307 336
28. D Nardelli-Haefliger D Wirthner JT Schiller 2003 Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles Journal of the National Cancer Institute 95 15 1128 1137
29. PM Day R Gambhira R Roden DR Lowy JT Schiller 2008 Mechanisms of HPV16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies Journal of Virology 82 9 4638 4646
30. MH Einstein 2008 Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines Cancer Immunology, Immunotherapy 57 4 443 451
31. A Hildesheim R Herrero S Wacholder 2007 Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial Jama 298 7 743 753
32. HW Chesson DU Ekwueme M Saraiya LE Markowitz 2008 Cost-effectiveness of human papillomavirus vaccination in the United States Emerging Infectious Diseases 14 2 244 251
33. RP Insinga 2006 Annual productivity costs due to cervical cancer mortality in the United States Womens Health Issues 16 5 236 242
34. RL Fleurence JM Dixon TF Milanova KM Beusterien 2007 Review of the economic and quality-of-life burden of cervical human papillomavirus disease American Journal of Obstetrics and Gynecology 196 3 206 212
35. T Pearman 2003 Quality of life and psychosocial adjustment in gynecologic cancer survivors Health and Quality of Life Outcomes 1 1 33
36. K Basen-Engquist ED Paskett J Buzaglo 2003 Cervical cancer Cancer 98 9 Suppl 2009 2014
37. M Idestrom I Milsom A Andersson-Ellstrom 2003 Women's experience of coping with a positive Pap smear: A register-based study of women with two consecutive Pap smears reported as CIN 1 Acta Obstetricia et Gynecologica Scandinavica 82 8 756 761
38. C Lerman SM Miller R Scarborough P Hanjani S Nolte D Smith 1991 Adverse psychologic consequences of positive cytologic cervical screening American Journal of Obstetrics and Gynecology 165 3 658 662
39. P Clarke C Ebel DN Catotti S Stewart 1996 The psychosocial impact of human papillomavirus infection: Implications for health care providers International Journal of STD and AIDS 7 3 197 200
40. A Filiberti M Tamburini B Stefanon 1993 Psychological aspects of genital human papillomavirus infection: A preliminary report Journal of Psychosomatic Obstetrics and Gynaecology 14 2 145 152
41. E Maissi TM Marteau M Hankins S Moss R Legood A Gray 2004 Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: Cross sectional questionnaire study Bmj 328 7451 1293
42. K McCaffery J Waller S Forrest L Cadman A Szarewski J Wardle 2004 Testing positive for human papillomavirus in routine cervical screening: Examination of psychosocial impact Bjog 111 12 1437 1443
43. BD Reed MT Ruffin DW Gorenflo P Zazove 1999 The psychosexual impact of human papillomavirus cervical infections Journal of Family Practice 48 2 110 116
44. BL Andersen 1996 Stress and quality of life following cervical cancer Journal of the National Cancer Institute. Monographs 21 65 70
45. DATA 2010. The Healthy People 2010 database. The Centers for Disease Control and Prevention. Available at http://wonder.cdc.gov/data2010/. Accessed 7 January 2008.
46. GD Coronado B Thompson TD Koepsell SM Schwartz D McLerran 2004 Use of Pap test among Hispanics and non-Hispanic whites in a rural setting Preventive Medicine 38 6 713 722
47. MG del Carmen M Findley A Muzikansky 2007 Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy Gynecologic Oncology 104 1 70 76
48. I De Alba JM Sweningson 2006 English proficiency and physicians' recommendation of Pap smears among Hispanics Cancer Detection and Prevention 30 3 292 296
49. K Behbakht A Lynch S Teal K Degeest S Massad 2004 Social and cultural barriers to Papanicolaou test screening in an urban population Obstetrics and Gynecology 104 6 1355 1361
50. JM Eisenberg 1979 Sociologic influences on decision-making by clinicians Annals of Internal Medicine 90 6 957 964
51. TT Nguyen SJ McPhee T Nguyen T Lam J Mock 2002 Predictors of cervical Pap smear screening awareness, intention, and receipt among Vietnamese-American women American Journal of Preventive Medicine 23 3 207 214
52. SJ Newmann EO Garner 2005 Social inequities along the cervical cancer continuum: A structured review Cancer Causes and Control 16 1 63 70
53. KA Phillips ML Mayer LA Aday 2000 Barriers to care among racial/ethnic groups under managed care Health Affairs (Millwood) 19 4 65 75
54. H Baer S Allen L Braun 2000 Knowledge of human papillomavirus infection among young adult men and women: Implications for health education and research Journal of Community Health 25 1 67 78
55. JE Ramirez DM Ramos L Clayton S Kanowitz AB Moscicki 1997 Genital human papillomavirus infections: Knowledge, perception of risk, and actual risk in a nonclinic population of young women J Womens Health 6 1 113 121
56. EK Adams N Breen PJ Joski 2007 Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and pap test utilization among white, Hispanic, and African American women: 1996-2000 Cancer 109 S2 348 358
57. Ryerson, A. B., Benard, V. B., & Major, A. C. (2005). The National Breast and Cervical Cancer Early Detection Program: 1991-2002 National Report. Atlanta: The Centers for Disease Control and Prevention.
58. The Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program. Available at http://www.cdc.gov/cancer/ nbccedp/. Accessed 29 March 2008.
59. Department of Health and Human Services. Medicaid Special Coverage Conditions. Breast and Cervical Cancer: Prevention and Treatment. Available at http://www.cms.hhs.gov/MedicaidSpecialCovCond/02-BreastandCervicalCancer- PreventionandTreatment.asp. Accessed 29 March 2008.
60. CDC. Racial and ethnic approaches to community health (REACH) 2010. The Centers for Disease Control and Prevention 2007. Available at http://www.cdc.gov/reach. Accessed 8 January 2008.
61. HP Freeman NA Vydelingum 2006 The role of the special populations networks program in eliminating cancer health disparities Cancer 107 8 Suppl 1933 1935
62. FE Jackson KC Chu R Garcia 2006 Special Populations Networks-how this innovative community-based initiative affected minority and underserved research programs Cancer 107 8 Suppl 1939 1944
63. CDC 2007 Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 56 1 24
64. LL Villa RL Costa CA Petta 2006 High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up British Journal of Cancer 95 11 1459 1466
65. The Future II Study Group 2007 Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions New England Journal of Medicine 356 19 1915 1927
66. Haupt, R. M. Gardasil update: End-of-study and adult women. Paper presented at ACIP, Atlanta, GA, 27 Feb 2008.
67. SE Olsson LL Villa RL Costa 2007 Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine Vaccine 25 26 4931 4939
68. LL Villa KA Ault AR Giuliano 2006 Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18 Vaccine 24 27-28 5571 5583
69. SL Giannini E Hanon P Moris 2006 Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 33-34 5937 5949
70. Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., et al., for the HPV PATRICIA study group. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 369(9580), 2161-2170.
71. DM Harper EL Franco CM Wheeler 2006 Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial Lancet 367 9518 1247 1255
72. Harper, D., Gall, S., Naud, P., et al. (2008). Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with cervarix TM (GSK's HPV 16/18 AS04 Candidate Vaccine). Paper presented at SGO Conference, Tampa, FL, 2008.
73. Gall, S., Teixeira, J., Wheeler, C., Naud, P., Harper, D. M., Franco, E. L., et al., on behalf of the HPV Vaccine Study Group. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. In Proceedings of the AACR Annual Meeting 2007. Available at http://www.aacr.org/home/scientists/meetings- workshops/annual-meeting-2007/publications.aspx. Accessed 18 April 2008.
74. Schwarz, T. F., & Dubin, G. (2007). Women HVSIfA. Human papillomavirus (HPV) 16/18 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well tolerated 18 months after vaccination in women up to 55 years. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 2007, 25, (18S (June 20 Supplement)).